Bradford Glavan, MD
Pulmonary Disease · Portland, ORNPI 1255441739
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $50 of the $68 with a category attached, or 73.8%. 3 manufacturers reported payments, led by Boston Scientific at 43.3% of the total. That places this record below the midpoint for pulmonary disease clinicians in OR, where the typical reported total is $402.
Across 4 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$30
- GSK$21
- CSL Behring$18
Across 21 payments — averaging $11,524 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$222K
- Sanofi US Services Inc.$20K
What the payments were for
- Food & beverage$5074%
- Education$1826%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $30 |
| GSK | 1 | $21 |
| CSL Behring | 1 | $18 |
How this compares
$68 in reported general payments places this provider in the 20th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 158 | $127,723 |
| Spiriva RespimatTiotropium Bromide | 41 | $35,233 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $18,367 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 57 | $17,142 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $15,860 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $10,260 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,678 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,829 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,155 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 139 | $6,182 |
| DuleraMometasone/Formoterol | 16 | $5,328 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,998 |
| Azithromycin | 87 | $1,550 |
| Montelukast Sodium | 78 | $990 |
| Fluticasone Propionate | 62 | $919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $21 | $161,950216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Portland
- Stephen YauPortland$984K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
- Steven SearsPortland$21K
- Melvin MorganrothPortland$14K
- Christina MacrostyPortland$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.